Imatinib treatment inhibit IL‐6, IL‐8, NF‐KB and AP‐1 production and modulate intracellular calcium in CML patients

Imatinib (IM) is considered the gold standard for chronic myeloid leukemia (CML) treatment, although resistance is emerging as a significant problem. The proinflammatory cytokines interleukin‐6 (IL‐6) and interleukin‐8 (IL‐8) play an important role in cell proliferation, survival, and resistance to glucocorticoid‐mediated cell death. Several transcription factors such as NF‐KB and AP‐1 are activated in response to physiopathological increases and modulation of intracellular calcium levels. Our previous study demonstrated that lymphocytes from CML patients showed dysregulated calcium homeostasis and oxidative stress. Alteration in ionized calcium concentration in the cytosol has been implicated in the initiation of secretion, contraction, and cell proliferation. In this study, we hypothesized that IL‐6, IL‐8, NF‐kB, AP‐1, and intracellular calcium may be used as selective and prognostic factors to address the follow‐up in CML patients treated with imatinib. Our results demonstrated a significant down‐regulation in IL‐6 and IL‐8 release as well as NF‐kB and AP‐1 activation in lymphomonocytes from Imatinib‐treated patients, compared to samples from untreated patients. In parallel, IM treatment, in vivo and in vitro, were able to modulate the intracellular calcium concentration of peripheral blood mononuclear cells of CML patients by acting at the level of InsP3 receptor in the endoplasmic reticulum and at the level of the purinergic receptors on plasma membrane. The results of this study show that measurements of NF‐kB, AP‐1, IL‐6, IL‐8, and intracellular calcium in CML patients treated with Imatinib may give important information to the hematologist on diagnostic criteria and are highly predictive in patients with newly diagnosed CML. J. Cell. Physiol. 227: 2798–2803, 2012. © 2011 Wiley Periodicals, Inc.

[1]  A. Giordano,et al.  Dysregulated calcium homeostasis and oxidative stress in chronic myeloid leukemia (CML) cells , 2010, Journal of cellular physiology.

[2]  Liang Guo,et al.  GADD45α mediates arsenite‐induced cell apoptotic effect in human hepatoma cells via JNKs/AP‐1‐dependent pathway , 2010, Journal of cellular biochemistry.

[3]  M. Dyer,et al.  Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells. , 2009, The Journal of clinical investigation.

[4]  R. Kurzrock,et al.  The prognostic significance of cytokine levels in newly diagnosed acute myeloid leukemia and high‐risk myelodysplastic syndromes , 2008, Cancer.

[5]  Andreas Hochhaus,et al.  Chronic myeloid leukaemia , 2007, The Lancet.

[6]  M. Karin.  NF‐κB and cancer: Mechanisms and targets , 2006 .

[7]  G. Kroemer,et al.  Targeting NF-κB in hematologic malignancies , 2006, Cell Death and Differentiation.

[8]  M. Galdiero,et al.  Interleukin-8 production by THP-1 cells stimulated by Salmonella enterica serovar Typhimurium porins is mediated by AP-1, NF-kappaB and MAPK pathways. , 2004, Cytokine.

[9]  Z. Estrov,et al.  Nuclear factor–κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis , 2004 .

[10]  F. E. Bertrand,et al.  JAK/STAT, Raf/MEK/ERK, PI3K/Akt and BCR-ABL in cell cycle progression and leukemogenesis , 2004, Leukemia.

[11]  Terry L. Smith,et al.  Expression of constitutively active nuclear-kappa B RelA transcription factor in blasts of acute myeloid leukemia. , 2004, Human pathology.

[12]  Paul Hofman,et al.  Imatinib induces mitochondria‐dependent apoptosis of the Bcr‐Abl‐positive K562 cell line and its differentiation toward the erythroid lineage 1 , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[13]  J. Blay,et al.  Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients , 2003, British Journal of Cancer.

[14]  K. Nakanishi,et al.  An Endoplasmic Reticulum Stress-specific Caspase Cascade in Apoptosis , 2002, The Journal of Biological Chemistry.

[15]  T. Cotter,et al.  High Bcr-Abl expression prevents the translocation of Bax and Bad to the mitochondrion , 2002, Leukemia.

[16]  T. Naka,et al.  The paradigm of IL-6: from basic science to medicine , 2002, Arthritis research.

[17]  M. Karin,et al.  AP-1 as a regulator of cell life and death , 2002, Nature Cell Biology.

[18]  T. van der Poll,et al.  Regulatory role of cytokines in disseminated intravascular coagulation. , 2001, Seminars in thrombosis and hemostasis.

[19]  J. Melo,et al.  The molecular biology of chronic myeloid leukemia. , 2000, Blood.

[20]  M. Mayo,et al.  The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. , 2000, Biochimica et biophysica acta.

[21]  J. Neary,et al.  Mitogenic Signaling by ATP/P2Y Purinergic Receptors in Astrocytes: Involvement of a Calcium-Independent Protein Kinase C, Extracellular Signal-Regulated Protein Kinase Pathway Distinct from the Phosphatidylinositol-Specific Phospholipase C/Calcium Pathway , 1999, The Journal of Neuroscience.

[22]  C. Sawyers.  Chronic myeloid leukemia. , 1999, The New England journal of medicine.

[23]  K. Anderson,et al.  Interleukin-6 Overcomes p21WAF1 Upregulation and G1 Growth Arrest Induced by Dexamethasone and Interferon-γ in Multiple Myeloma Cells , 1997 .

[24]  Christopher C. Goodnow,et al.  Differential activation of transcription factors induced by Ca2+ response amplitude and duration , 1997, Nature.

[25]  M. Sitkovsky,et al.  Murine T lymphocytes modulate activity of an ATP-activated P2Z-type purinoceptor during differentiation. , 1996, Journal of immunology.

[26]  Jürg Zimmermann,et al.  Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr–Abl positive cells , 1996, Nature Medicine.

[27]  F. Virgilio.  The P2Z purinoceptor: an intriguing role in immunity, inflammation and cell death , 1995 .

[28]  A. Lichtenstein,et al.  Interleukin-6 inhibits apoptosis of malignant plasma cells. , 1995, Cellular immunology.

[29]  B. Klein,et al.  Interleukin-6 in human multiple myeloma. , 1995, Blood.

[30]  B. Barlogie,et al.  Interleukin-6 prevents dexamethasone-induced myeloma cell death. , 1994, Blood.

[31]  P. Fenaux,et al.  Modulation of IL-8, IL-1 beta, and G-CSF secretion by all-trans retinoic acid in acute promyelocytic leukemia. , 1994, Leukemia.

[32]  J. Kienast,et al.  Cytokine response to infection in patients with acute myelogenous leukaemia following intensive chemotherapy , 1994, British journal of haematology.

[33]  A. Strife,et al.  Linkage of proliferative and maturational abnormalities in chronic myelogenous leukemia and relevance to treatment. , 1993, Leukemia.

[34]  M. Jourdan,et al.  Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. , 1990, European cytokine network.

[35]  O. Witte,et al.  Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. , 1990, Science.

[36]  L. Heppel,et al.  Extracellular ATP is a mitogen for 3T3, 3T6, and A431 cells and acts synergistically with other growth factors. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[37]  R. Tsien,et al.  A new generation of Ca2+ indicators with greatly improved fluorescence properties. , 1985, The Journal of biological chemistry.

[38]  C. McCall,et al.  Independent stimulation of motility and the oxidative metabolic burst of human polymorphonuclear leukocytes. , 1978, Journal of immunology.

[39]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[40]  Oliver H. Lowry,et al.  Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.

[41]  M. Karin.  NF-kappaB and cancer: mechanisms and targets. , 2006, Molecular carcinogenesis.

[42]  G. Kroemer,et al.  Targeting NF-kappaB in hematologic malignancies. , 2006, Cell death and differentiation.

[43]  P. Claudio,et al.  Medroxyprogesterone acetate increases anthracyclines uptake in chronic lymphatic leukemia cells: role of nitric oxide and lipid peroxidation. , 2000, Anticancer research.

[44]  L. Chan.  The Molecular Biology of Chronic Myeloid Leukaemia , 1998 .

[45]  T. Meyer,et al.  Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. , 1996, Cancer research.

[46]  L. Heppel,et al.  Extracellular ATP is a mitogen for 3 T 3 , 3 T 6 , and A 431 cells and acts synergistically with other growth factors ( purinoceptor / competence factor / ectoenzymes ) , 2022 .